

Tabel 3 Potentiële therapeutische targets in Graves' ophthalmopathie

<b>Therapeutisch target</b>	<b>Medicijn</b>	<b>Omschrijving medicijn</b>
<i>therapeutisch target: cytokine of groeifactor</i>		
IL-1 $\beta$	canakinumab	anti-IL-1 $\beta$ monoklonale antistof
IL-1 receptor	anakinra	IL-1 receptor antagonist
IL-6	tocilizumab	anti-IL-6 monoklonale antistof
PDGF –receptor	imatinib, nilotinib, dasatinib	remmers tyrosinekinase activiteit PDGF-receptor
TGF- $\beta$	lerdelimumab, GC1008	anti-TGF- $\beta$ monoklonale antistoffen
TGF- $\beta$ signalering	imatinib, nilotinib, dasatinib	remmers tyrosinekinase activiteit c-Abl
TNF- $\alpha$	adalimumab, infliximab	anti-TNF- $\alpha$ monoklonale antistoffen
TNF	etanercept	TNF receptor-IgG Fc fusie-eiwit
<i>therapeutisch target: immuuncel</i>		
CD3	otelixizumab, teplizumab	anti-CD3 monoklonale antistoffen
CD20	rituximab, ocrelizumab, ofatumumab	anti-CD20 monoklonale antistoffen
CD28	abatacept	CTLA-4-IgG fusieeiwit
CD154	toralizumab	anti-CD154-monoklonale antistof
<i>andere targets</i>		
Zuurstofradicalen	selenium	sporenelement in voeding
PPAR- $\gamma$	selectieve PPAR modulatoren	PPAR- $\gamma$ antagonisten
Somatostatine receptor	SOM230	synthetisch somatostatine analoog
TSH-receptor	NIDDK/CDB-52	laag moleculaire TSH-receptor antagonist